Challenges and considerations in the immunotherapy of DLL3-positive small-cell lung cancer using IL-18 armoured chimeric antigen receptor T-cells

Roberta Mazza; John Maher; Caroline M Hull

doi:10.21037/tlcr-23-793

Challenges and considerations in the immunotherapy of DLL3-positive small-cell lung cancer using IL-18 armoured chimeric antigen receptor T-cells

Transl Lung Cancer Res. 2024 Mar 29;13(3):678-683. doi: 10.21037/tlcr-23-793. Epub 2024 Mar 18.

Authors

Roberta Mazza¹, John Maher^{1

2

3}, Caroline M Hull¹

Affiliations

¹ Leucid Bio Ltd., Guy's Hospital, London, UK.
² School of Cancer and Pharmaceutical Sciences, King's College London, Guy's Hospital, London, UK.
³ Department of Immunology, Eastbourne Hospital, Eastbourne, UK.

No abstract available

Keywords: Delta-like ligand 3 (DLL3); armoured CAR T-cells; immunotherapy; interleukin-18-secreting chimeric antigen receptor T-cells (IL-18-secreting CAR T-cells); small-cell lung cancer (SCLC).

Publication types

Editorial
Comment